



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1094-1-028DIV
	SERIAL NO.	10/646,268
	APPLICANT	Mark Marchionni et al.
	FILING DATE	August 22, 2003
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (INFORMATION DISCLOSURE STATEMENT)	GROUP	1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	C L A S S	SUB- CLA SS	FILING DATE IF APPROPRIATE
	AA	5,530,109	6/25/96	Goodearl et al.			
	AB	5,716,930	2/10/98	Goodearl et al.			
	AC	3,773,919	11/20/73	Boswell et al.			
	AD	4,179,337	12/18/79	Davis et al.			
	AE	4,301,144	11/17/81	Iwashita et al.			
	AE	4,485,045	11/27/84	Regen			
	AG	4,485,045	1/29/85	Mitra			
	AH	4,544,545	10/1/85	Ryan et al.			
	AE	4,640,835	2/3/87	Shimizu et al.			
	AJ	4,670,417	6/2/87	Iwasaki et al.			
	AK	4,791,192	12/13/88	Nakagawa et al.			
	AL	5,367,060	11/22/94	Vandlen et al.			
	AM	5,641,869	6/24/97	Vandlen et al.			
	AN	5,667,780	9/16/97	Ho et al.			
	AO	5,714,385	2/3/98	Mather et al.			

EXAMINER: /Sharon Wen/	DATE CONSIDERED: 08/27/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 2 of 8

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1094-1-028DIV
	SERIAL NO.	10/646,268
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (INFORMATION DISCLOSURE STATEMENT)	APPLICANT	Mark Marchionni et al.
	FILING DATE	August 22, 2003
	GROUP	1644

	AP	5,721,139	2/24/98	Mather et al.			
	AQ	5,834,229	11/10/98	Vandlen et al.			
	AR	5,840,525	11/24/98	Vandlen et al.			
	AS	5,856,110	1/5/99	Vandlen et al.			
	AT	5,859,206	1/12/99	Vandlen et al.			
	AU	5,968,511	10/19/99	Akita et al.			
	AV	6,033,660	3/7/00	Mather et al.			
	AW	6,087,323	7/11/00	Gwynne et al.			
	AX	6,096,873	8/1/00	Schaefer et al.			
	AY	6,121,415	9/19/00	Godowski et al.			
	AZ	6,136,558	10/24/00	Ballinger et al.			
	ABA	6,156,728	12/5/00	Gao			
	ABB	6,162,641	12/19/00	Goldman et al.			
	ABC	6,169,070	1/2/01	Chen et al.			
	ABD	6,252,051	6/26/01	Godowski et al.			
	ABE	6,387,638	5/14/02	Ballinger et al.			
	ABF	6,399,746	6/4/02	Vandlen et al.			
	ABG	6,444,642	9/3/02	Sklar et al.			
	ABH	6,446,242	9/3/02	Lien et al.			

EXAMINER: /Sharon Wen/	DATE CONSIDERED: 08/27/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Sheet 3 of 6

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1094-1-028DIV
	SERIAL NO.	10/646,268
	APPLICANT	Mark Marchionni et al.
	FILING DATE	August 22, 2003
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (INFORMATION DISCLOSURE STATEMENT)	GROUP	1644

	AB I	6,593,290	7/15/03	Gao			
	ABJ	6,635,249	10/21/03	Marchionni et al.			
	ABK	6,750,196	6/15/04	Reh et al.			
	ABL	7,037,888	5/2/06	Sklar et al.			
	ABM	7,226,907	6/5/07	Zhou			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	C L A S S	SUB- CLA SS	TRANSLATION YES NO
	BA	WO 97/09425	3/13/97	PCT			
	BB	0 102 324	3/7/84	Europe			
	BC	0 133 988	8/1/84	Europe			
	BD	0 052322	3/27/85	Europe			
	BE	0 058481	10/1/86	Europe			
	BF	0 088 046	12/9/87	Europe			
	BG	0 143 949	10/12/88	Europe			
	BH	0 036 676	9/19/90	Europe			

EXAMINER: /Sharon Wen/	DATE CONSIDERED: 08/27/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Sheet 4 of 8

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1094-1-028DIV
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (INFORMATION DISCLOSURE STATEMENT)	SERIAL NO.	10/646,268
	APPLICANT	Mark Marchionni et al.
	FILING DATE	August 22, 2003
	GROUP	1644

	BI	0 142 641	1/16/91	Europe			
	BJ	0 647 449	6/23/94	Europe			
	BK	WO 89/01489	2/23/89	PCT			
	BL	WO 92/18627	10/29/92	PCT			
	BM	WO 94/00140	1/6/94	PCT			
	BN	WO 94/26298	11/24/94	PCT			
	BO	WO 95/32724	12/7/95	PCT			
	BP	WO 96/15812	5/30/96	PCT			
	BQ	WO 99/18976	4/22/99	PCT			
	BR	DE 3218121	5/14/82	Germany			
	BS	AU -B-68278/94	12/12/94	Australia			
	BT	58-118008 (Abstract only)	1/16/85	Japan			

EXAMINER: /Sharon Wen/	DATE CONSIDERED: 08/27/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Sheet 5 of 8

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1094-1-028DIV
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (INFORMATION DISCLOSURE STATEMENT)	SERIAL NO.	10/646,268
	APPLICANT	Mark Marchionni et al.
	FILING DATE	August 22, 2003
	GROUP	1644

--	--	--	--	--	--	--	--

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Burden et al., Neuregulins and Their Receptors: A Versatile Signalling Module in Organogenesis and Oncogenesis, Neuron, 18:847-855 (1997)
CB	Busfield et al., Characterization of a Neuregulin-Related Gene, <i>Don-1</i> , That is Highly Expressed in Related Regions of the Cerebellum and Hippocampus, Mol. Cell. Biol., 17:4007-4014 (1997)
CC	Caraway et al., Neuregulin-2, a new ligand of ErbB3/ErbB4-Receptor Tyrosine Kinases, Nature, 387:512-516 (1997)
CD	Chang et al., Ligand for ErbB-family Receptors Encoded by a Neuregulin-like Gene, Nature, 387:509-512 (1997)
CE	Holmes et al., Identification of Heregulin, A Specific Activator of p185 ^{erbB2} , Science 256:1205-1210 (1992)
CF	Lemke, Neuregulins in Development, Mol. Cell. Neurosci. 7:247-262 (1996)
CG	Marchionni et al., Glial Growth Factors are Alternatively Spliced erbB2 Ligands expressed in the Nervous System, Nature 362:312-318 (1993)
CH	Meyer et al., Isoform-specific Expression and Function of Neuregulin, Development 124:3575-3586 (1997)
CI	Peles et al., Isolation of the NeuHER-2 Stimulatory Ligand: A 44 kd Glycoprotein that Induces Differentiation of Mammary Tumor Cells, Cell 69:205-216 (1992)
CJ	Bargmann et al., "The Neu oncogene encodes an epidermal growth factor receptor-related protein" Nature 319:226-230, 1986
CK	Chen et al., "Expression of Multiple Neuregulin Transcripts in Postnatal Rat Brains: J. Comp. Neurol. 349: 389-400, 1994
CL	Corfas et al., "Differential Expression of ARIA Isoforms in the Rat Brain" Neuron 14: 103-115, 1995

EXAMINER: /Sharon Wen/	DATE CONSIDERED: 08/27/2009
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Sheet 6 of 8

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1094-1-028DIV
	SERIAL NO.	10/646,268
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (INFORMATION DISCLOSURE STATEMENT)	APPLICANT	Mark Marchionni et al.
	FILING DATE	August 22, 2003
	GROUP	1644

CM	Falls et al., "ARIA, A Protein that Stimulates Acetylcholine Receptor Synthesis, is a member of the Neu ligand Family" Cell 72: 801-815, 1993
CN	Higashiyama et al., "A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4" J. Biochem. (Tokyo) 122:675-680, 1997
CO	Hijazi et al., "NRG-3 in human breast cancers: activation of multiple erbB family proteins: Int. J. Oncol. 13:1051-1067, 1998
CP	Kraus, et al., Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors" Proc. Natl. Acad. Sci. USA 86: 9193-9197, 1989
CQ	Meyer et al., "Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development" Proc. Natl. Acad. Sci. USA 91: 1064-1068, 1994
CR	Orr-Urtreger et al., "Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21" Proc. Natl. Acad. Sci. USA 90: 1867-1871, 1993
CS	Plowman et al., "Ligand-specific activation of HER4/p180 ^{neu} , a fourth member of the epidermal growth factor receptor family" Proc. Natl. Acad. Sci. USA 90: 1746-1750, 1993
CT	Sarker et al., "Quantitative analysis of Her-2/neu (ERBB2) gene expression using reverse transcriptase polymerase chain reaction" Diagn. Mol. Pathol. 2:210-218, 1993
CU	U.S. Application Serial No. 08/461,097 filed 06/05/1995
CV	Wen et al., Neu Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit" Cell 69:559-572, 1992
CW	Zhao et al., "Neuregulins Promote Survival and Growth of Cardiac Myocytes." Journal of Biological Chemistry 273:10261-10269, 1998
CX	Peles and Yarden, Neu and its Ligands: From an Oncogene to Neural factors, BioEssays 15:815-824 (1993)
CY	Pinkas-Kramarski et al., Differential Expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of Neuronal Differentiation, Oncogene 15:2803-2815 (1997)

EXAMINER: /Sharon Wen/	DATE CONSIDERED: 08/27/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Sheet 7 of 8

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	1094-1-028DIV
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (INFORMATION DISCLOSURE STATEMENT)	SERIAL NO.	10/646,268
	APPLICANT	Mark Marchionni et al.
	FILING DATE	August 22, 2003
	GROUP	1644

CZ	Pinkas-Kramarski et al., Brain Neurons and Glial Cells Express neu Differential Factor/Heregulin A Survival Factor for Astrocytes, Proc. Natl. Acad. Sci. USA 91:9387-9391 (1994)
CAA	Pinkas-Kramarski et al., ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor network, Mol. Cell. Biol. 18:6090-6101 (1998)
CAB	Zhang et al., Neuregulin-3 (NRG3): A Novel Neural Tissue-Enriched Protein That Binds and Activates ErbB4, Proc. Natl. Acad. Sci. USA 94:9562-9567 (1997)
CAC	The Merck Manual of Diagnosis and Therapy, 17th Edition, pages 1682-1692 (1999)
CAD	Balligand et al., Cardiac Endothelium and Tissue Growth, Progress in Cardiovascular Diseases, 39:351-360 (1997)
CAE	Chien et al., Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response, The FASEB Journal, 5:3037-3046 (1991)
CAF	Dias et al., The Molecular Basis of Skeletal Muscle Differentiation, Seminars in Diagnostic Pathology, 11:3-14 (1994)
CAG	Epstein et al., Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor, Proc. Natl. Acad. Sci. USA, 82:3688-3692 (1985)
CAH	Florini et al., Stimulation of Myogenic Differentiation by a Neuregulin, Glial Growth Factor 2, J. Biol. Chem., 271:12699-12702 (1996)
CAI	Hwang et al., Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study, Proc. Natl. Acad. Sci. USA, 77:4030-4034 (1980)
CAJ	Langer et al., Biocompatibility of polymeric delivery systems for macromolecules, Journal of Biomedical Material Research, 15:267-277 (1981)
CAK	Parker et al., p53-Independent Expression of p21 ^{Cip1} in Muscle and Other Terminally Differentiating Cells, Science, 267:1024-1027 (1995)
CAL	Physician's Desk Reference, Medical Economics Data Production Co., Montvale, NJ, 2314-2320 (1994)

EXAMINER: /Sharon Wen/	DATE CONSIDERED: 08/27/2009
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

